Kruppel-like factor 2 might mediate the rapamycin-induced arterial thrombosis in vivo: Implications for stent thrombosis in patients

Chinese Medical Journal

Volumn 126, Issue 14, 2013, Pages 2636-2640

  Nie, Xiao Min ^a   Su, Li Xiao ^a   Xu, Rui Xia ^b   Guo, Yuan Lin ^b   Zhou, Yu Jie ^a   Li, Jian Jun ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Adenovirus; Gene expression; Krupple like factor 2; Rapamycin; Thrombosis

Indexed keywords

ADENOVIRUS VECTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAPAMYCIN; THROMBOMODULIN; THROMBOPLASTIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; GENE; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSCRIPTION; KRUPPEL LIKE FACTOR 2 GENE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STENT THROMBOSIS; WESTERN BLOTTING;

ANIMALS; CAROTID ARTERIES; DRUG-ELUTING STENTS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE III; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIROLIMUS; THROMBOMODULIN; THROMBOSIS;

EID: 84880468739     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130704     Document Type: Article

References (33)

1. Urban P, Abizaid A, Banning A, Bartorelli AL, Baux AC, Dzavik V, et al. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT registry. J Am Coll Cardiol 2011; 57: 1445-1454.
2. Han YL. Drug-eluting stent: where is the way out? Chin Med J 2013; 126: 1005-1007.
3. Räber L, Jüni P, Nüesch E, Kalesan B, Wenaweser P, Moschovitis A, et al. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol 2011; 57: 2143-2151.
4. Maeng M, Tilsted HH, Jensen LO, Kaltoft A, Kelbæk H, Abildgaard U, et al. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus and sirolimus-eluting coronary stents. JACC Cardiovasc Interv 2012; 5: 812-818.
5. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis biological mechanisms and clinical implications. Circulation 2007; 115: 1051-1058.
6. Steffel J, Latini RA, Akhmedov L. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005; 112: 2002-2011.
7. Camici GG, Steffel J, Amanovic I. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur Heart J 2010; 31: 236-242.
8. Gyöngyösi M, Strehblow C, Sperker W. Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: prothrombogenic response of drug-eluting or bare stent implantation within the first 24 hours. Thromb Haemost 2006; 96: 202-209.
9. Muldowney JA, Stringham JR, Levy SE. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 2007; 27: 400-406.
10. Jabs A, Munzel T. Drug-eluting stent-induced vascular dysfunction: common and missing links. J Am Coll Cardiol 2010; 55: 1399-1400.
11. Cheng C, Tempel D, Oostlander A. Rapamycin modulates the eNOS vs. shear stress relationship. Cardiovasc Res 2008; 78: 123-129.
12. Dekker RJ, Boon RA, Rondaij MG. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 2006; 107: 4354-4363.
13. Atkins GB, Jain MK. Role of Krüppel-like transcription factors in endothelial biology. Cir Res 2007; 100: 1686-1689.
14. Parmar KM, Larman HB, Dai G. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest 2006; 116: 49-58.
15. Dekker RJ, van Thienen JV, Rohlena J, de Jager SC, Elderkamp YW, Seppen J, et al. Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. Am J Pathol 2005; 167: 609-618.
16. Lin ZY, Kumar A, SenBanerjee S. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Cir Res 2005; 96: e48-e56.
17. SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, et al. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 2004; 199: 1305-1315.
18. Young A, Wu W, Sun W, Larman HB, Wang N, Li YS, et al. Flow activation of AMP-activated protein kinase in vascular endothelium leads to Kruppel-like factor 2 expression. Arterioscler Thromb Vasc Biol 2009; 29: 1902-1908.
19. Xu RX, Chen JH, Cong XG, Hu SS, Chen XI. Lovastatin protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2. J Cell Biochem 2008; 103: 256-269.
20. Li JJ, Ueno H, Tomita H, Yamamoto H, Kanegae Y, Saito I, et al. Adenovirus-mediated arterial gene transfer dose not require prior injury for submaximal gene expression. Gene Ther 1995; 2: 351-354.
21. Li JJ, Ueno H, Pan Y, Tomita H, Yamamoto H, Kanegae Y, et al. Percutaneous transluminal gene transfer into canine myocardial in vivo by replication-defective adenovirus. Cardiovasc Res 1995; 30: 97-105.
22. Lemesle G, Maluenda G, Collins SD, Waksman R. Drug-eluting stents: issues of late stent thrombosis. Cardiol Clin 2010; 28: 97-105.
23. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164-2170.
24. US Food and Drug Administration, Center for Devices and Radiological Health. CYPHER sirolimus-eluting coronary stent on RAPTOR over-the-wire delivery system or RAPTORRAIL rapid exchange delivery system. (Accessed December 17, 2004 at http://www.fda.gov/cdrh/pdf2/p020026.html)
25. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, et al. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002; 13: 183-188.
26. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188-1193.
27. Sabatini DM, Erdjument-Bromage H, Lui M. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35-43.
28. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
29. Viswambharan H, Ming XF, Zhu S, Hubsch A, Lerch P, Vergères G, et al. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphate-dylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res 2004; 94: 918-925.
30. Blum S, Issbrüker K, Willuweit A, Hehlgans S, Lucerna M, Mechtcheriakova D, et al. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem 2001; 276: 33428-33434.
31. Sako K, Fukuhara S, Minami T, Hamakubo T, Song H, Kodama T, et al. Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2. J Biol Chem 2009; 284: 5592-5601.
32. Huddleson JP, Ahmad N, Lingrel JB. Up-regulation of the KLF2 transcription factor by fluid shear stress requires nucleolin. J Biol Chem 2006; 281: 15121-15128.
33. van Thienen JV, Fledderus JO, Dekker RJ, Rohlena J, van Ijzendoorn GA, Kootstra NA, et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc Res 2006; 72: 231-240.